Once recognised and treated appropriately, the available data suggest that the prognosis for OSAS is very good and reverts to that of the non-OSAS population, particularly in terms of cardiovascular mortality and morbidity. However, because patients with significant sleepiness need symptomatic treatment with CPAP, it is not ethically acceptable to undertake long-term randomised, placebo-controlled  trials in the optimal population to determine its effect on cardiovascular morbidity and mortality; rather, the evidence has to be obtained more indirectly from case-controlled or cohort studies with all of their inherent biases.


See the entire Sleep breathing disorders Chapter